Spanish CDMO 3PBIOVIAN has announced that it has signed a contract to carry out the development of a biosimilar monoclonal antibody (mAb) for an oncology indication with the National Cancer Institute (Instituto Nacional de Cancerología) in Colombia.
The biosimilar mAb will be the first developed specifically to expand access to oncology treatments in Colombia.
The announcement reveals that the agreement covers the full development process, including cell line and analytical method development, production scale-up and technology transfer to the client's facilities in Colombia for manufacturing products for patient care.
For 3PBIOVIAN, the contract represents a "significant milestone" in strengthening its track record in full mammalian development, from cell line creation through industrial-scale process transfer.
The company said the agreement also allows it to participate in the highly important initiative to expand patient access to valuable cancer therapeutics.
For 3PBIOVIAN's Colombian partner, the project is a strategic step forward for the country's biopharmaceutical industry, aligned with national efforts to build local biomanufacturing capacity and reduce dependence on imported biologics.
"We are proud to contribute to this project, which truly reflects 3PBIOVIAN's purpose: to enable global access to high-quality biopharmaceuticals," said Dámaso Molero, Group CEO.
This collaboration reinforces our experience in mammalian development programmes and our commitment to international partnerships that make a real impact on patients' lives.
The project represents an innovative initiative for Colombia, driven by the ambition to expand access to affordable biologic medicines.
The production of this biosimilar mAb is expected to improve access to oncology treatments for Colombian patients and to strengthen the country's biotechnological sovereignty.